Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share and a growing global cannabis platform following its acquisition of Sanity Group GmbH ("Sanity"), today provided a business update highlighting initial operating performance from Sanity, continued strength in its Canadian business, and upcoming investor engagement.

"The first quarter following the acquisition of Sanity marks an important milestone for Organigram as we will begin reporting the financial contribution from our international business," said James Yamanaka, Chief Executive Officer. "Sanity's initial performance has been consistent with our expectations at the time of acquisition, while our Canadian business continues to demonstrate resilience through market leadership, improving category trends and disciplined execution. We look forward to providing investors with our first full quarter of consolidated financial results in August and discussing our longer-term strategy during our investor session in September."

Sanity Group Performance1

The Company is providing investors with an initial update on Sanity's operating performance following the completion of the acquisition in April 2026.

Since the closing of the acquisition on April 15, 2026, Sanity has maintained an average market share of approximately 10% in Germany and has performed in line with the revenue expectations established at the time of acquisition, supporting management's confidence in the long-term opportunity within Germany's growing medical cannabis market.

The Company also notes that recently announced regulatory changes in Germany2 regarding reimbursement eligibility for medical cannabis are not expected to have a material impact on Sanity's business, as reimbursement-based sales represent approximately 1% of Sanity's total revenue.

Canadian Market Share

Organigram continues to maintain leading positions across Canada's largest cannabis categories, including:

• #1 in Flower - 12.5% share of the flower category;
• #1 in Vapes - 14.5% share of the vape category
• #2 in Pre-rolls - 7.3% share of the pre-roll category.

Together, these categories represent more than 86% of total Canadian recreational cannabis retail sales.

The Company also recorded significant year-over-year market share gains in beverages (+3.1 percentage points) and concentrates (+3.3 percentage points).

During June, Organigram stabilized the vape market share declines experienced earlier in Q2 Fiscal 2026, with all-in one vape share improving approximately 1 percentage point compared to the previous month. Distribution of the Company's new all-in-one vape portfolio has now expanded to every Canadian province except Nova Scotia and Quebec.

Similarly, both pre-roll and infused pre-roll market share improved sequentially during June, reflecting operational improvements implemented during Q2 Fiscal 2026.

At the end of June, Organigram held 11.1% Canadian recreational cannabis market share, down 0.4 percentage points year-over-year. Sequentially, the Company’s market share improved 100 basis points versus May. Sequential market share improvements in June across vape and pre-roll categories provide positive early indicators that the commercial and operational initiatives put in place in Q2 fiscal 2026 are beginning to positively impact performance.

The Company continues optimizing its SKU count to focus its resources on delivering higher SKU-level performance and delivering operational efficiencies across the board.

Q3 Fiscal 2026 Reporting & Digital Investor Session

Organigram expects to report its Q3 Fiscal 2026 financial results on or about August 11, 2026, representing the first quarter to include consolidated financial results from both Organigram and Sanity.